Results 1 to 10 of about 72,295 (296)

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab

Drugs in R&D, 2023
Background Adalimumab-aqvh/CHS-1420 (YUSIMRYTM) (hereafter referred to as adalimumab-aqvh) was recently approved by the US Food and Drug Administration as a biosimilar for adalimumab.
Yijia Jiang, Taruna Arora, Scott Klakamp, Janice Davis, Yasmin A. Chandrasekher, Glen Young, Yue Du, Bin Yu, Karen J. Miller   +8 more
doaj   +2 more sources

Long-Term Dose Optimization of Adalimumab via Dose Spacing in Patients with Psoriasis [PDF]

Bioengineering, 2022
Dose spacing (DS) can be useful for optimizing treatment with biologics in psoriasis patients. However, interval prolongation might increase the production of anti-drug antibodies (ADA) and, therefore, reduce the drug’s effectiveness.
Michael Benzaquen, Mohammad Munshi, Simon Bossart, Laurence Feldmeyer, Vladimir Emelianov, Nikhil Yawalkar, Simone Cazzaniga, Kristine Heidemeyer   +7 more
doaj   +3 more sources

Analysis of Suffix Use for Biosimilar Product Identification in Postmarketing Adverse Event Reporting. [PDF]

Clin Pharmacol Ther
Accurate identification of medicines used in adverse event reports is crucial for effective postmarketing safety surveillance. The US Food and Drug Administration's (FDA) four‐letter suffix naming convention was designed to facilitate accurate biological product identification, but the extent to which these suffixes have been incorporated into ...
Stojanovic D, Wolf L, Ricci MS, Muñoz MA.   +3 more
europepmc   +2 more sources

Residual Burden in Adalimumab-Treated Patients with Hidradenitis Suppurativa: An Observational Cohort Study Based on Insurance Claims in the USA [PDF]

Drugs - Real World Outcomes
Introduction Hidradenitis suppurativa (HS), a chronic, inflammatory skin disease, causes significant morbidity. Until 2023, adalimumab was the only US-approved biologic for patients with moderate to severe HS.
Maria A. Aleshin, Tanja Tran, Ingrid Pansar, Aijing Shang, David Friesen, Alexa B. Kimball   +5 more
doaj   +2 more sources

Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With Psoriasis.

JAMA dermatology, 2021
Importance The efficacy of adalimumab biosimilars is similar to that of brand-name adalimumab (Humira, hereinafter originator) in clinical trials. However, limited knowledge about real-world data exists for adalimumab biosimilars.
N. Loft, A. Egeberg, M. Rasmussen, L. Bryld, Christoffer V. S. Nissen, T. N. Dam, K. Ajgeiy, L. Iversen, L. Skov   +8 more
semanticscholar   +2 more sources

Outcomes of adalimumab biosimilar nonmedical switches in children and young adults with inflammatory bowel disease. [PDF]

JPGN Rep
Abstract Objectives Adalimumab biosimilars are as safe and effective compared to the originator. Adult patients with inflammatory bowel disease (IBD) who switched to a biosimilar have comparable outcomes, but pediatric data are limited. This study evaluates clinical outcomes of children and young adults with IBD following a nonmedical, insurance‐driven
Himelstein D, McNicol M, Abdel-Rasoul M, Boyle BM, Michel HK, Maltz R.   +5 more
europepmc   +2 more sources

Adalimumab Monotherapy in a Patient with Psoriatic Arthritis Associated with Chronic Renal Failure on Hemodialysis: A Case Report and Literature Review

Clinical Medicine Insights: Case Reports, 2012
We report a patient with psoriatic arthritis (PsA) who was successfully treated with adalimumab even while under hemodialysis therapy for associated chronic renal failure. Flow cytometry of circulating lymphocytes revealed an obvious decrease in both Th1
Yasuhiro Shimojima, Masayuki Matsuda, Wataru Ishii, Shu-ichi Ikeda   +3 more
doaj   +2 more sources

Management of Crohn's disease in poor responders to adalimumab

Clinical and Experimental Gastroenterology, 2014
Nanne KH de Boer,1 Mark Löwenberg,2 Frank Hoentjen3 1Department of Gastroenterology and Hepatology, VU University Medical Center, Amsterdam, the Netherlands; 2Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, the ...
de Boer NKH, Löwenberg M, Hoentjen F   +2 more
doaj   +1 more source

Adalimumab Monotherapy vs Adalimumab With Methotrexate for Psoriasis [PDF]

Importance: It is unclear whether concomitant methotrexate enhances the effectiveness and persistence of adalimumab for psoriasis. The recent OPTIMAP randomized clinical trial that tested adalimumab against adalimumab with methotrexate could not ...
Richard, Warren, Hampton, Philip J., Laws, Philip, Yiu, Zenas, Smith, Catherine H; id_orcid, Griffiths, Christopher   +5 more
core   +11 more sources

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.

The Lancet, 2022
BACKGROUND Active-comparator trials are important to inform patient and physician choice. We aimed to evaluate the efficacy and safety of monotherapy with either ustekinumab or adalimumab in biologic-naive patients with moderately to severely active ...
B. Sands, P. Irving, T. Hoops, J. Izanec, Long-Long Gao, C. Gasink, A. Greenspan, M. Allez, S. Danese, S. Hanauer, V. Jairath, T. Kuehbacher, James D. Lewis, E. Loftus, E. Mihály, R. Panaccione, E. Scherl, O. Shchukina, W. Sandborn   +18 more
semanticscholar   +1 more source